From GlobeNewswire: 2025-06-19 09:10:00

The Uveitis Treatment Market was valued at USD 2.26 billion in 2023 and is projected to reach USD 4.69 billion by 2032, growing at a CAGR of 8.47%. Factors contributing to this growth include advancements in biologic therapies, targeted treatments, and sustained-release drug delivery systems. The U.S. market is expected to reach USD 1.44 billion by 2032, with a CAGR of 8.09%, driven by a robust healthcare infrastructure and investments in ophthalmic research.

Major players in the Uveitis Treatment Market include AbbVie Inc., Santen Pharmaceutical Co., Ltd., Bausch Health Companies Inc., Regeneron Pharmaceuticals Inc., and more. Corticosteroids hold the largest market share in uveitis treatment, while the anterior uveitis segment dominates due to its simplicity in diagnosis and treatment. Retail pharmacies are the leading distribution channel, offering convenience and accessibility to patients.

North America leads the Uveitis Treatment Market, with the U.S. at the forefront due to its advanced healthcare system and regulatory support for innovative therapies. The Asia-Pacific region is expected to register the fastest growth, driven by increased healthcare expenditure and awareness of autoimmune diseases. Emerging economies like China and India are making rapid progress in health-related infrastructure, enhancing access to eye-related treatments.



Read more at GlobeNewswire: Uveitis Treatment Market Size to Reach USD 4.69 Billion by